Tufts Center for the Study of Drug Development (CSDD) and Medable reported an eNPV-based analysis indicating Medable’s AI clinical monitoring agent can generate net financial gains of up to $21 million per oncology program, with return on investment up to 82x in Phase 3. The modeling attributed value to operational efficiencies, including reductions in on-site visits and travel, faster patient enrollment, and shorter database lock timelines. Tufts said the AI agent accelerated development by about 18 weeks in the analyzed scenarios and produced direct operating cost reductions of roughly $4.4 million in Phase 2 and $5.6 million in Phase 3. Medable said the study used actual use and benchmark data to quantify the financial impact of an “agentic” AI solution supporting drug development workflows. The next step is a peer-reviewed publication later this year, according to the release.